Sanofi’s Generics Sales Stabilize Post-Zentiva
Emerging Markets Now Account For The Bulk Of Generics Turnover
Reporting its fourth-quarter and full-year 2019 results, Sanofi saw an overall drop in generics sales following 2018’s divestment of Zentiva in Europe but enjoyed consistent turnover in emerging markets. Moreover, fourth-quarter generics turnover showed a stabilization of the business once the Zentiva comparison is removed.
You may also be interested in...
The second part of Generics Bulletin’s newly-compiled global sales ranking of generics and biosimilars companies sees a number of major firms sliding up and down the table.
After seemingly stabilizing late last year, Sanofi has seen its generics sales once again drop in the first quarter of 2020, despite moving past unfavorable prior-year comparisons with the Zentiva generics business which the company divested in 2018.
Ensuring that Zentiva has the necessary strategy, skills, competencies, capabilities and people to operate independently as a “leading European generics player” is a key priority, the company’s head, Patrick Aghanian, told Generics bulletin as the firm started life as an independent company under the ownership of private-equity investor Advent International.